FDA approves first quadrivalent intradermal influenza vaccine
the ONA take:
Sanofi Pasteur has announced that the U.S. Food and Drug Administration (FDA) has approved Fluzone Intradermal Quadrivalent vaccine. A trivalent formulation of the vaccine has been available for 3 years, but the quadrivalent formulation will help to protect against four strains of influenza rather than three.
The vaccine is approved for adults aged 18 to 64 years for the prevention of infection by influenza A and B subtypes. The trivalent vaccine protects against two influenza A subtypes and only one influenza B subtype, but it is influenza B that is a common cause of morbidity and morality associated with influenza.
The most common adverse effects observed in clinical trials were erythema, headache, induration at the injection site, malaise, myalgia, pain, pruritus, and swelling. These reactions typically occurred within 3 days of vaccination and were mild to moderate in severity.
In addition, the intradermal vaccines is equally as effective as an intramuscular flu shot. Like other flu shots, the Fluzone Intradermal Quadrivalent vaccine should not be administered to patients with egg allergies or to anyone who has experienced a hypersensitivity reaction to a previous influenza vaccine.
The FDA has approved Fluzone Intradermal Quadrivalent vaccine for influenza.
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
- Distress Management Tool Gets an Update, Patient Version
- PSA Screening Rates Level Off in United States
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|